🟢 GILD.BA is trading 3.1% up today after FDA approval of Trodelvy for first-line breast cancer treatment

GILD.BA is trading 3.1% up now at $49,320 after the U.S. FDA approved Gilead’s antibody-drug conjugate Trodelvy for first-line treatment of metastatic triple-negative breast cancer.

• The landmark approval expands Trodelvy into the initial treatment setting, authorizing its use both as a monotherapy and in combination with Merck’s Keytruda.
• This development is viewed as a major growth driver for Gilead’s oncology portfolio, helping the stock outperform a slightly weaker broader market.